GlassScriptPhysician profile
Andrew J Mustin
NPI 1083616528
$9,350.37
in general payments reported to CMS, 2019-2025
41 companies · $433 in 2025
The $433 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,682 · 2020: $438 · 2021: $1,862 · 2022: $1,562 · 2023: $1,883 · 2024: $1,491 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,043.80 | 2019-2025 | |
| Amgen INC. | $984.75 | 2019-2025 | Repatha |
| Pfizer INC. | $888.56 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $845.86 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $728.28 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $645.86 | 2019-2025 | Watchman Flx, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $633.03 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $533.38 | 2019-2025 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $503.94 | 2019-2023 | |
| Amarin Pharma, INC. | $344.95 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.75 | 2019-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $194.59 | 2024 | Arcalyst |
| Astellas Pharma US INC | $185.50 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $161.18 | 2019-2024 | Evkeeza |
| Esperion Therapeutics, INC. | $156.05 | 2021-2024 | Nexletol |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $144.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Edwards Lifesciences Corporation | $115.60 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.38 | 2019-2024 | Lifevest |
| Althera Pharmaceuticals LLC | $84.97 | 2021 | |
| Arbor Pharmaceuticals, INC. | $83.86 | 2020-2022 | |
| Medtronic, INC. | $82.47 | 2022-2024 | Linq II, Mycarelink, Micra |
| Bayer Healthcare Pharmaceuticals INC. | $77.51 | 2021-2022 | |
| Irhythm Technologies, INC. | $61.04 | 2021-2022 | |
| Philips North America LLC | $53.69 | 2021-2023 | |
| Lundbeck LLC | $51.15 | 2019-2021 | |
| Abbott Laboratories | $48.10 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Kiniksa Pharmaceuticals, LTD. | $35.97 | 2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $33.80 | 2019-2024 | Optimizer |
| Daiichi Sankyo INC. | $28.60 | 2024 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $25.30 | 2021 | |
| Baxter Healthcare | $23.69 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Kestra Medical Technology Services, INC. | $23.20 | 2024 | Assure Wcd |
| Braemar Manufacturing, LLC | $22.18 | 2019 | |
| Preventice Services, LLC | $20.58 | 2019 | |
| Portola Pharmaceuticals, LLC | $20.08 | 2019 | |
| Agepha Pharma Fz LLC | $19.19 | 2024 | Lodoco |
| Scpharmaceuticals INC. | $18.55 | 2023 | |
| Biogen, INC. | $18.02 | 2024 | Skyclarys |
| Azurity Pharmaceuticals, INC. | $16.54 | 2023 | Edarbi |
| Biotronik INC. | $15.71 | 2019 | |
| Medtronic Vascular, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mustin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.